Neoadjuvant PD-1 Blockade Seems Effective in Glioblastoma
Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma.
Brain Tumors
Statins, NSAIDS Have No Apparent Survival Benefit for Grade IV Glioma
In certain parts of the analysis, the use of selective COX-2 inhibitors and metamizol was associated with inferior patient survival.
Novel Glioblastoma Treatment Granted Orphan Drug Designation
In preclinical models, the inhibition of phosphorylated STAT3 (p-STAT3) by WP1066 resulted in the direct attack of various tumor cells.
Sex Differences ID’d in Response to Glioblastoma Treatment
Standard therapy is more effective for female vs male patients with glioblastoma.
Nivolumab + Ipilimumab Shows Efficacy for Untreated Brain Mets
For patients with melanoma and untreated brain metastases, nivolumab combined with ipilimumab shows clinically meaningful efficacy.
Modified Polio Vaccine Looks Promising in Early Glioblastoma Trial
PVSRIPO is a prototypic oncolytic recombinant polio virus vaccine that recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors.
Child Neuroblastoma Survivors at Risk for Psych Impairment
Neuroblastoma survivors are at elevated risk for psychological impairment.
Quality of Life in Glioblastoma Not Worsened by Tumor-Treating Fields Plus Temozolomide
Participants receiving TTFields with temozolomide experienced significantly longer deterioration-free survival for global health vs those receiving temozolomide only.
Clinical Factors Associated With Pediatric Brain Neoplasms
A study pinpointed clinical factors associated with pediatric brain neoplasms to assist clinicians in making neuroimaging decisions.
No Survival Benefit With Lomustine Plus Bevacizumab in Glioblastoma
Treatment with lomustine plus bevacizumab does not show a survival advantage over treatment with lomustine alone in patients with glioblastoma.
Next post in Brain Tumors
